Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcoma

Ducimetiere, 2011, Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing, PLoS One, 6, e20294, 10.1371/journal.pone.0020294 Schoffski, 2016, Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial, Lancet, 387, 1629, 10.1016/S0140-6736(15)01283-0 Judson, 2014, Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial, Lancet Oncol, 15, 415, 10.1016/S1470-2045(14)70063-4 Sleijfer, 2010, Eur J Cancer, 46, 72, 10.1016/j.ejca.2009.09.022 Benjamin, 1975, Adriamycin: a new effective agent in the therapy of disseminated sarcomas, Med Pediatr Oncol, 1, 63, 10.1002/mpo.2950010109 Borden, 1987, Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas, J Clin Oncol, 5, 840, 10.1200/JCO.1987.5.6.840 Van Glabbeke, 1999, J Clin Oncol, 17, 150, 10.1200/JCO.1999.17.1.150 van Oosterom, 2002, Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients, Eur J Cancer, 38, 2397, 10.1016/S0959-8049(02)00491-4 Lorigan, 2007, Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study, J Clin Oncol, 25, 3144, 10.1200/JCO.2006.09.7717 Bentzen, 2000, Fractionated radiotherapy for metastatic bone pain: evidence-based medicine or...?, Int J Radiat Oncol Biol Phys, 46, 681, 10.1016/S0360-3016(99)00397-1 Antman, 1993, An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas, J Clin Oncol, 11, 1276, 10.1200/JCO.1993.11.7.1276 Patel, 1997, High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies—dose-response and schedule dependence, J Clin Oncol, 15, 2378, 10.1200/JCO.1997.15.6.2378 Sutton, 1996, Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study, Gynecol Oncol., 62, 226, 10.1006/gyno.1996.0220 Le Cesne, 2000, J Clin Oncol, 18, 2676, 10.1200/JCO.2000.18.14.2676 Penel, 2010, Factors affecting the outcome of patients with metastatic leiomyosarcoma treated with doxorubicin-containing chemotherapy, Ann Oncol, 21, 1361, 10.1093/annonc/mdp485 Hensley, 2002, Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial, J Clin Oncol, 20, 2824, 10.1200/JCO.2002.11.050 Hensley, 2008, Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial, Gynecol Oncol, 109, 329, 10.1016/j.ygyno.2008.03.010 Beatrice M, Seddon JW, Strauss Sandra J, et al. GeDDiS: a prospective randomised controlled phase III trial of gemcitabine and docetaxel compared with doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft tissue sarcomas (EudraCT 2009-014907-29). 2015 ASCO Annual Meeting 2015. Le Cesne, 2005, Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial, J Clin Oncol, 23, 576, 10.1200/JCO.2005.01.180 Schoffski, 2016, Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial, Lancet., 387, 1629, 10.1016/S0140-6736(15)01283-0 Hamaji, 2016, Surgical and non-surgical management of repeat pulmonary metastasis from sarcoma following first pulmonary metastasectomy, Surg Today., 10.1007/s00595-016-1312-x Santoro, 1995, Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group, J Clin Oncol, 13, 1537, 10.1200/JCO.1995.13.7.1537 Edmonson, 1993, Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas, J Clin Oncol, 11, 1269, 10.1200/JCO.1993.11.7.1269 Worden, 2005, Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma, J Clin Oncol, 23, 105, 10.1200/JCO.2005.05.108 Maurel, 2009, Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas, J Clin Oncol, 27, 1893, 10.1200/JCO.2008.19.2930 Fayette, 2009, Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma, Invest New Drugs, 27, 482, 10.1007/s10637-008-9217-1